Post by : mbilalfares | Post on : September 14, 2022 at 12:50 pm
ND Biosciences’ publishes a new paper in collaboration with the EPFL and ADX NeuroScience describing thorough characterization of 3 ELISA immunoassays that are most commonly used in clinical studies, demonstrating that these assays do not accurately measure the diversity and complexity of alpha-synuclein (aSYN) species in biological fluids. The d
Read morePost by : mbilalfares | Post on : January 14, 2022 at 12:17 pm
ND Biosciences awarded a grant from The Michael J. Fox Foundation to accelerate the development of its assays for early diagnosis of Parkinson’s disease and monitoring disease progression ND Biosciences announced today that it was awarded a grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate its diagnostics rese
Read morePost by : mbilalfares | Post on : October 11, 2021 at 9:56 am
ND-BioSciences Announces partnership with The Michael J. Fox Foundation for parkinson’s research to make available unique synuclein proteoforms to the scientific community Given ND Biosciences’ commitment to deploy its expertise, technical capabilities and integrated platforms to accelerate the discovery and validation of novel targets and
Read morePost by : mbilalfares | Post on : October 7, 2021 at 4:34 am
ND BioSciences, a Swiss-based biotechnology company that was
Read more